LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

KeyBanc thinks newly-public Israeli beauty stock is underappreciated in healthcare technology

Chaim Potok by Chaim Potok
August 15, 2023
in Investing
KeyBanc thinks newly-public Israeli beauty stock is underappreciated in healthcare technology
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


Investors are overlooking Oddity Tech , which is poised to become a leader in the growing digital beauty and wellness market, according to KeyBanc. Analyst Scott Schoenhaus initiated coverage of the Israeli beauty company with an overweight rating and assigned a price target of $60, suggesting shares stand to gain more than 29% in the next 12 months. “We see ODD in the early stages of its growth story, with near-term tailwinds from its ongoing disruption of beauty and wellness end markets but longer-term growth opportunities that can be unlocked given its unique, differentiated technology,” Schoenhaus wrote in a Monday note. Oddity’s use of its “nascent hyperspectral technology” and a company-owned biotechnology asset — both powered by AI — will lead to novel beauty and wellness treatments, KeyBanc said. Oddity, a direct-to-consumer platform known for its Il Makiage and Spoiled Child brands, invested more than $100 million in April to acquire biotech startup Revela , which will use AI-based molecule discovery to target cosmetics pain points, such as hair loss and aging. “We see large potential opportunities for these assets being utilized for more acute care in dermatology (acne treatment will be the focus of the upcoming third brand launch in 2025) such as eczema, psoriasis, melanoma screening, etc., that could be deployed and are being underappreciated by the market, from our unique perspective, in healthcare technology,” the analyst said. Oddity’s revenue grew at about 43% compound annual growth rate in the last three years, driven by online, digital sales, (which still only account for 21% of the total market), and expansion of existing brands to boost market share and introduction of new brands in growth areas, KeyBanc said. Oddity’s legacy IL Makiage brand comprises about 2% of the total beauty market, the note said. Oddity went public in July at $35 a share in an IPO led by Goldman Sachs, Morgan Stanley and Allen & Co., climbing 36% on its first day of trading and giving it a a current market value of $2.6 billion. — CNBC’s Michael Bloom contributed reporting.



Source link

You might also like

Tuesday’s big stock stories: What’s likely to move the market in the next trading session

Nasdaq 100 momentum unmatched since 1999 so brace for a shakeout, says BTIG

This big bank stock still has upside ahead despite its 20% year-to-date rally, investor says

Share30Tweet19
Previous Post

Tenant jailed after conning kind-hearted landlord out of £212,000 – LandlordZONE

Next Post

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Chaim Potok

Chaim Potok

Recommended For You

Tuesday’s big stock stories: What’s likely to move the market in the next trading session
Investing

Tuesday’s big stock stories: What’s likely to move the market in the next trading session

July 22, 2025
Nasdaq 100 momentum unmatched since 1999 so brace for a shakeout, says BTIG
Investing

Nasdaq 100 momentum unmatched since 1999 so brace for a shakeout, says BTIG

July 21, 2025
This big bank stock still has upside ahead despite its 20% year-to-date rally, investor says
Investing

This big bank stock still has upside ahead despite its 20% year-to-date rally, investor says

July 21, 2025
This is one of the most attractive opportunities for income, Vanguard says. Here’s what the firm likes
Investing

This is one of the most attractive opportunities for income, Vanguard says. Here’s what the firm likes

July 21, 2025
Next Post
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Related News

Toyota is ‘loading the bases’ with a wave of new hybrid, PHEV, and EVs

Toyota is ‘loading the bases’ with a wave of new hybrid, PHEV, and EVs

May 28, 2025
London rabbi who lost family in West Bank shooting ‘feels safer in Israel than UK’

London rabbi who lost family in West Bank shooting ‘feels safer in Israel than UK’

October 20, 2023
President Biden signs executive order to promote AI infrastructure

President Biden signs executive order to promote AI infrastructure

January 14, 2025

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?